Engineered t cells take on leukemia in early trial
NCT ID NCT01044069
First seen May 04, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This early-stage study tests a new treatment for B-cell acute lymphoblastic leukemia (B-ALL) using a patient's own immune cells, called T cells. The T cells are collected from the blood, genetically modified in a lab to recognize and attack leukemia cells, and then infused back into the patient. The main goal is to check the safety and find the right dose of these modified cells in adults with B-ALL that has returned or not responded to standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.